Lastly, studying the potential of the BAs-FXR signaling pathway as a therapeutic target for specific conditions, such as non-alcoholic fatty liver disease, type 2 diabetes, and cancer [124]. Here, NR1H4 is linked to metabolic dysfunction-associated steatotic liver disease.